Forecast

The analysts' average price target is +2,57€ (+29,15%). The median is +2,57€ (+29,15%).

Buy	11
Hold	1
Sell	0

News Go to news feed

ProQR shares fall despite positive data on AX-0810 and pipeline progress

ProQR shares slipped about 3% even though Phase 1 data from the first cohort for AX-0810 showed no serious adverse events and the pharmacokinetics matched the nonclinical data. Target-engagement data for AX-0810 are expected in the first half of 2026. ProQR also selected AX-2402 (Rett syndrome, MECP2-R270X) and AX-2911 (MASH, PNPLA3) as development candidates after convincing preclinical results, and received $4.5 million in milestone payments from Eli Lilly in 2025, extending its cash runway to mid-2027. » More on de.investing.com
ProQR receives EMA approval for phase-1 trial of RNA-editing therapy AX-0810

The CCMO has granted ProQR permission to start a phase-1 trial of the RNA-editing agent AX-0810 in healthy volunteers. The approval was issued under the new centralized EMA review procedure and permits dosing in the Netherlands. The study will assess safety, tolerability, and pharmacokinetics and -dynamics using biomarkers; AX-0810 is the first Axiomer program to enter clinical development. ProQR will hold a virtual investor event on Nov. 3; an analyst most recently confirmed a "Market Outperform" rating with a $8.00 price target. » More on de.investing.com
ProQR submits application for clinical trial of RNA editing therapy AX-0810

ProQR has submitted an application to the European Medicines Agency for a Phase 1 clinical trial of its RNA editing therapy AX-0810, which targets cholestatic liver diseases. Initial data are expected in the fourth quarter of 2025, while analysts highlight the company's strong position in RNA editing and its promising pipeline. Additionally, key leadership positions have been filled with Dennis Hom as CFO and Cristina Lopez Lopez as CMO to advance clinical development. » More on de.investing.com

Financials

In the last quarter, ProQR Therapeutics had revenue of 8.90m€ and net profit of −8.87m€

(EUR)	Jun 2026	YoY
Revenue	+8.90m	133,27%
Gross profit	+8.19m	114,44%
Net profit	−8.87m	27,15%
EBITDA	−8.25m	28,18%

Fundamentals

Metric	Value
Market capitalization	+212.37m€
Number of shares	105.31m
52-week high/low	+2,66€ - +1,14€
Dividends	No
Beta	0,03
P/E ratio	−5,09
PEG ratio	−0,88
P/B ratio	+2,79
P/S ratio	+11,43

Company profile

ProQR Therapeutics N.V., ein biopharmazeutisches Unternehmen, beschäftigt sich mit der Entdeckung und Entwicklung von RNA-basierten Therapeutika für die Behandlung von genetischen Erkrankungen. Es entwickelt in erster Linie Sepofarsen, das sich in der klinischen Phase II/III-Studie Illuminate zur Behandlung der kongenitalen Leber-Amaurose 10 befindet, und Ultevursen, das sich in der klinischen Phase II/III-Studie zur Behandlung der USH2A-vermittelten Retinitis pigmentosa und des Usher-Syndroms befindet. Das Unternehmen befasst sich auch mit der Entwicklung der Axiomer RNA-Base-Editing-Plattformtechnologie. Es hat eine Lizenzvereinbarung mit dem Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc. und dem Leiden University Medical Center sowie eine Lizenz- und Forschungskooperation mit Eli Lilly and Company für die Entdeckung, Entwicklung und Vermarktung potenzieller neuer Medikamente für genetische Störungen der Leber und des Nervensystems. ProQR Therapeutics N.V. wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in Leiden, Niederlande.

Name	ProQR Therapeutics
CEO	Daniel Anton de Boer
Headquarters	Leiden, zh Netherlands
Website	proqr.com
Sector	Health Care
Industry	Biotechnology
IPO	09/18/2014
Employees	166